Eli Lilly shares weekly forecast: Strong rally approaches overbought territory while support remains at $1,200

Traders Union
All News
Stocks
Eli lilly gains 6.73% this week

Highlights

Shares of Eli Lilly surged 6.7% over the past week to $1,260, confirming strong upward momentum.
Technical structure remains bullish with prices well above key moving averages and heightened volatility at 11.1%.
Over the next five days, shares are expected to consolidate between $1,202 and $1,317 with high probability of further gains.

Record highs this week on upgraded guidance and new approvals

LLY reached new highs after strong second-quarter earnings and a raised full-year 2026 revenue forecast from $82–85 billion to $85–87 billion, with robust sales from Zepbound and Mounjaro fueling optimism, according to TipRanks and Investing.com. The company's weight-loss pill Foundayo received its first European approval in the UK for both weight management and type 2 diabetes on August 10, 2024, as reported by Yahoo Finance. LLY further expanded its global pipeline through new R&D collaborations in neuroscience and lung cancer, and broadened access to Zepbound in the US via the Employer Connect platform.

Bullish momentum stretches as overbought signals intensify this week

The daily chart shows a sharp move higher without a sustained trend, with volatility over the past week at 11.1%. Momentum readings are stretched to the upside, as CCI is in overbought territory at 208.35 while the RSI is approaching overbought. The nearest support is at $1,200, derived from the Ichimoku Kijun, and resistance is at $1,292, drawn from the weekly high. This setup points to continued bullish bias but with potential for consolidation as overbought signals build.

Sideways consolidation expected as breakout risks rise next week

Over the next five trading days, Eli Lilly shares are expected to trade within a range of $1,202 to $1,317. There is a very high probability (more than 80%) of further gains and a very low probability (less than 20%) of a decline. The base case calls for sideways action to consolidate inside this range. A break above $1,292 would open room for further upside toward $1,317, while a move below $1,200 support could see the stock slip toward $1,202.

Viktoras Karapetjanc, Traders Union expert, sees Eli Lilly's rally last week as a reflection of robust fundamentals and strong market sentiment. He notes that upbeat earnings results, pipeline expansion, and regulatory approvals have fueled optimism, keeping the bullish structure intact even as technical readings turn overbought. While consolidation is likely as the stock digests extreme momentum, a breakout above $1,292 may unlock further upside toward $1,317. The risk of a retracement appears limited with the $1,200 level offering solid support. "This week, I expect Eli Lilly to maintain its leadership — the combination of innovation, strong guidance, and investor demand signals further growth potential in the coming days."

Earlier, analysts noted that Eli Lilly's growth was underpinned by strong product momentum and expanding R&D partnerships, while cautioning about possible short-term technical risks. The current setup builds on this outlook, as recent earnings strength and new product approvals reinforce the prevailing bullish scenario, but traders should monitor the $1,200 support as a key risk level going forward.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.